Stock REGN34 REGENERON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Regeneron Pharmaceuticals, Inc. Sao Paulo

Equities

REGN34

BRREGNBDR005

Market Closed - Sao Paulo
Other stock markets
 02:23:40 2024-07-16 pm EDT 		5-day change 1st Jan Change
99.06 BRL +26.37% Intraday chart for Regeneron Pharmaceuticals, Inc. +3.08% +45.44%
Jul. 12 UBS Raises Price Target on Regeneron Pharmaceuticals to $1,250 From $1,124, Maintains Buy Rating MT
Jul. 11 Morgan Stanley Trims Price Target on Regeneron Pharmaceuticals to $1,182 From $1,183 MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Regeneron Expects Earnings Hit After $24 Million R&D Charge
DJ
Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval
MT
EU approves Sanofi's Dupixent for 'smoker's lungs'
RE
Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD
CI
Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
CI
Regeneron, Sanofi Eosinophilic Esophagitis Treatment Showed Improvements for Children in Phase 3 Study
MT
Regeneron Pharmaceuticals, Inc Announces Dupixent® Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
CI
FDA approves Verona Pharma's therapy for 'smoker's lungs'
RE
Bayer's pharmaceutical unit plans more managerial cuts in Europe, Asia
RE
Alvotech Enters Commercialization Deal for Eylea Biosimilars with Advanz Pharma
MT
Regeneron Pharmaceuticals, Inc. Announces 14-Month Median Follow-Up Data from the Pivotal Phase 1/2 Linker-MM1 Trial of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma
CI
Regeneron Pharmaceuticals Wins Injunctions Against Biosimilars to Eye Disease Drug Eylea
MT
Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Has Approves Kevzara®
CI
FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier
MT
Fibrogen, Inc. Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals, Inc. to Evaluate FibroGen's Immuno-Oncology Assets, Fg-3175 (Anti-Ccr8), in Upcoming Clinical Trials
CI
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review
RE
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months
MT
Regeneron Pharmaceuticals, Inc and Sanofi Announce Dupixent® Recommends for EU Approval by the CHMP to Treat Patients with COPD
CI
Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation
CI
Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. REGN Stock
  4. REGN34 Stock
  5. News Regeneron Pharmaceuticals, Inc.
  6. Highlights